Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

neuroendocrine neoplasms

  • You have access
    64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection
    Mathias Loft, Esben A. Carlsen, Camilla B. Johnbeck, Helle H. Johannesen, Tina Binderup, Andreas Pfeifer, Jann Mortensen, Peter Oturai, Annika Loft, Anne K. Berthelsen, Seppo W. Langer, Ulrich Knigge and Andreas Kjaer
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 73-80; DOI: https://doi.org/10.2967/jnumed.120.244509
  • Prognostic Value of <sup>18</sup>F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
    You have access
    Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
    Jingjing Zhang, Qingxing Liu, Aviral Singh, Christiane Schuchardt, Harshad R. Kulkarni and Richard P. Baum
    Journal of Nuclear Medicine November 1, 2020, 61 (11) 1560-1569; DOI: https://doi.org/10.2967/jnumed.119.241414
  • You have access
    18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients
    Tina Binderup, Ulrich Knigge, Camilla Bardram Johnbeck, Annika Loft, Anne Kiil Berthelsen, Peter Oturai, Jann Mortensen, Birgitte Federspiel, Seppo W Langer and Andreas Kjaer
    Journal of Nuclear Medicine October 16, 2020, jnumed.120.244798; DOI: https://doi.org/10.2967/jnumed.120.244798
  • You have access
    Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
    Jingjing Zhang, Harshad R. Kulkarni, Aviral Singh, Karin Niepsch, Dirk Müller and Richard P. Baum
    Journal of Nuclear Medicine March 1, 2019, 60 (3) 377-385; DOI: https://doi.org/10.2967/jnumed.118.215848
  • You have access
    Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients
    Camilla B. Johnbeck, Ulrich Knigge, Seppo W. Langer, Annika Loft, Anne Kiil Berthelsen, Birgitte Federspiel, Tina Binderup and Andreas Kjaer
    Journal of Nuclear Medicine December 1, 2016, 57 (12) 1851-1857; DOI: https://doi.org/10.2967/jnumed.116.174714
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire